Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 18Terminated 3Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 9Genitourinary 7CNS 6Sarcoma 5Myeloid 4Gastrointestinal 4Gynecologic 3Thoracic 2Plasma cell 2Other solid neoplasm 2Breast 2Dermatologic 1

Conditions

Ovarian Neoplasms 3Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Carcinoma, Ovarian Epithelial 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × sargramostim × Gynecologic × Clear all
NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Marker Therapeutics, Inc.

Phase 2 Terminated
120 enrolled 12 charts
Gynecologic

Ovarian Neoplasms

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
21 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00023634 2015-03-06

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

SWOG Cancer Research Network

Phase 1 Terminated
14 enrolled
CNSGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Astrocytoma, Brain Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡